NCT05081583 - Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 16, 2021

Primary Completion Date

January 16, 2023

Study Completion Date

August 31, 2023

Conditions

Interaction, Adverse Herb-DrugDiabetes Mellitus, Type 2

Interventions

DRUG

Midazolam Hcl 1Mg/Ml Inj

0.5 mL of an intravenous solution (1 mg/mL) will be administered.

DIETARY_SUPPLEMENT

Goldenseal (Hydrastis canadensis)

Goldenseal (Solaray; Lot #1020199) is supplied as dried root powder in vegetable capsules, each containing 550 mg of herbal content. Goldenseal capsules will be administered with 240 mL of water.

Trial Locations (1)

99202

Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane

All Listed Sponsors

collaborator

National Center for Complementary and Integrative Health (NCCIH)

NIH

lead

Washington State University

OTHER